Evidence map›Paper›PMID 41269527›Full record

ArticleJournal of cancer survivorship : research and practice2025

Longitudinal associations of chemotherapy-induced peripheral neuropathy with psychological distress and health-related quality of life in colorectal cancer survivors: a prospective cohort study.

N D Boekhoudt, F Mols, C Simons, N R Querido, S O Breukink, L Valkenburg-van Iersel, M L G Janssen-Heijnen, E T P Keulen, M P Weijenberg, M J L Bours

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

N D BoekhoudtDepartment of Epidemiology, GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
F MolsDepartment of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands.
C SimonsDepartment of Epidemiology, GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
N R QueridoDepartment of Epidemiology, GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
S O BreukinkDepartment of Surgery, GROW Research Institute for Oncology and Reproduction, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands.
L Valkenburg-van IerselDepartment of Internal Medicine, Division of Medical Oncology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands.
M L G Janssen-HeijnenDepartment of Epidemiology, GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
E T P KeulenDepartment of Internal Medicine and Gastroenterology, Zuyderland Medical Centre Sittard-Geleen, Geleen, The Netherlands.
M P WeijenbergDepartment of Epidemiology, GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
M J L BoursDepartment of Epidemiology, GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. m.bours@maastrichtuniversity.nl.

Funding

Kankeronderzoekfonds Limburg, The Netherlands 00005739KWF Kankerbestrijding UM 2010-4867KWF Kankerbestrijding UM 2012-5653KWF Kankerbestrijding UM 2021-1/13387World Cancer Research Fund International 2016/1620World Cancer Research Fund International 2017/1619
6 · The paper itself

Abstract

purposeColorectal cancer (CRC) survivors receiving oxaliplatin-based chemotherapy frequently develop chemotherapy-induced peripheral neuropathy (CIPN). This study investigated the impact of CIPN symptoms on psychological distress and health-related quality of life (HRQoL) among oxaliplatin-treated CRC survivors up to 5 years post-treatment.

methods124 CRC patients treated with oxaliplatin-based chemotherapy participating in a prospective cohort study were included in the longitudinal analyses. CIPN symptoms were measured at diagnosis (pre-treatment) and at 6 weeks and 6, 12, 24, and 60 months post-treatment using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN20 (EORTC QLQ-CIPN20). Psychological distress, including anxiety and depressive symptoms, and HRQoL were measured at all post-treatment time points using the Hospital Anxiety and Depression Scale (HADS) and the EORTC QLQ-Core 30 (EORTC QLQ-C30), respectively. Confounder-adjusted longitudinal associations of CIPN symptoms with psychological distress and HRQoL were analysed with linear mixed regression models.

resultsCIPN symptoms in oxaliplatin-treated CRC patients were highest at 6 weeks post-treatment, thereafter gradually decreasing over time. More severe CIPN symptoms were longitudinally associated with more psychological distress (HADS), including both higher anxiety and depressive symptoms, and with worse global health/QoL and physical and social functioning and more fatigue (EORTC QLQ-C30).

conclusionCIPN symptoms, persisting over time among oxaliplatin-treated CRC survivors, were longitudinally associated with more psychological distress and lower HRQoL up to 5 years after chemotherapy treatment. IMPLICATIONS FOR CANCER SURVIVORS: CIPN symptoms following oxaliplatin-based chemotherapy have a long-lasting impact on CRC survivors. Research on interventions aimed at mitigating CIPN symptoms is warranted.

Indexed as

Cancer survivorsChemotherapy-induced peripheral neuropathyColorectal cancerHealth-related quality of lifePsychological distress

Identifiers

PMID41269527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.